New award for ranibizumab (LUCENTIS) syringes with genentech USA, INC. Period of performance is 12/23/23 to 12/22/24 with four one-year options.

Active Indefinite Delivery Contract Awarded Last action

Contract number
36E79724D0001
Awardee
Awarding agency
Task orders
0

Award facts

Opportunity
Last date to order 96% complete
IDV ceiling
$3,011,580.00
Award type
Single award
Set-aside
No set-aside
Competition
Full and Open Competition · 3 offers Negotiated Proposal / Quote
Pricing
Firm Fixed Price

Award details come from SAM.gov/FPDS.

About this IDV

Written by GovTribe AI ·

The National Acquisition Center awarded an indefinite-delivery contract to Genentech USA, Inc. on December 23, 2023, for ranibizumab (Lucentis) syringes, with a ceiling of $3.01 million and an ultimate completion date of December 22, 2026. It is a single award with no set-aside. The requirement originated in a pre-solicitation posted June 15, 2023, with responses due July 13, 2023, and no set-aside was used. The base period runs December 23, 2023, through December 22, 2024, followed by four one-year options. A modification changes the manufacturing and packaging location for the ranibizumab syringes.

Transactions

Action Obligated Date
Other Administrative Action P00015 · Modification to change the manufacturing and packaging location for ranibizumab (LUCENTIS) syringes for genentech contract 36E79724D0001. $0
Supplemental Agreement for work within scope P00013 · Implementing EO 14398 DEI discrimination $0
Other Administrative Action P00011 · Authorize credits and rebills due to database pricing error. $0
Add Subcontract Plan P00010 · Incorporate genentech's 2026 subk plan into contract. Plan effective 1/1/2026 - 12/31/2026. $0
Exercise an Option P00009 · Exercise the second option year for ranibizumab (LUCENTIS) syringes contract 36E79724D0001 with genentech USA, INC. With price changes. $0
Supplemental Agreement for work within scope P00008 · Incorporation of the 2026 federal ceiling prices with genentech contract 36E79724D0001 with price adjustments. $0
Add Subcontract Plan P00007 · Incorporate genentech's 2025 subk plan into contract. Plan effective 1/1/2025 - 12/31/2025. $0
Supplemental Agreement for work within scope P00006 · Incorporation of the 2025 federal ceiling prices with genentech contract 36E79724D0001 with price adjustments. $0
Exercise an Option P00005 · Exercise the first option year for ranibizumab (LUCENTIS) syringes contract 36E79724D0001 with genentech USA, INC. With no price changes. $0
Add Subcontract Plan P00004 · Incorporate genentech's corrected 2024 subk plan into contract. Plan effective 1/1/2024 - 12/31/2024. $0
Supplemental Agreement for work within scope P00003 · Update to cost recovery fee (CRF) and submission of quarterly sales reports 36E79724D0001, genentech USA, INC. For ranibizumab (LUCENTIS) syringes. $0
Other Administrative Action P00002 · Incorporation of 2024 federal ceiling price into contract. The awarded national contract price remains unchanged. $0
Add Subcontract Plan P00001 · Incorporate the approved 2024 commercial company wide subcontracting plan for genentech USA, INC. For the period of 1/1/24 to 12/31/24. $0
Original award $0
Show all 14

Quick answers

Who was awarded contract 36E79724D0001?

36E79724D0001 was awarded to Genentech Usa, Inc. by National Acquisition Center (Headquarters) on December 23, 2023.

How much is contract 36E79724D0001 worth?

36E79724D0001's own ceiling is $3,011,580.

Who can order from contract 36E79724D0001?

36E79724D0001 is a single award indefinite delivery contract.

Was contract 36E79724D0001 competed?

The extent of competition for 36E79724D0001 was full and open competition. The government received 3 offers.

On GovTribe

See this IDV's full record

  • Every order and transaction
  • The awardee's other awards and teaming partners
  • Similar IDVs and recompete opportunities
  • Ask GovTribe AI about this IDV
Try for free Login